[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647287":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":26,"collaborators":11,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":11,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":11,"enrollmentInfo":37,"targetDuration":11,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":11,"overallStatus":46,"whyStopped":11,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":11},{"fullName":5,"class":6},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ntravenous Chelators in Lead-Burdened Type 2 Diabetic Nephropathy","EXPERIMENTAL",null,[13],"Drug: chelator",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","chelator","Calcium Disodium Edetate Injection",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Xin Li","CONTACT","0579-89935390","903706017@qq.com",{"type":27,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100647287","intravenous-chelators-in-lead-burdened-type-2-diabetic-nephropathy-100647287",false,"NCT07706946","Intravenous Chelators in Lead-Burdened Type 2 Diabetic Nephropathy","A Prospective Study on Intravenous Chelator Therapy for Slowing Renal Function Progression in Patients With Type 2 Diabetic Nephropathy Combined With Lead Burden","Inclusion Criteria:\n\n* 1\\. Diagnosed with type 2 diabetic nephropathy; 2. Baseline blood lead level ≥5 µg\u002Fdl; 3. Chronic kidney disease stage ≤3; 4. 24-hour urinary protein \\\u003C 8 g; 5. Age ≥18 years old; 6. Able to provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Combined hypertension; 2. Combined hyperlipidemia; 3. History of autoimmune diseases; 4. Personal history of malignant tumors; 5. Reversible renal insufficiency (malignant hypertension, urinary tract infection, recent use of nephrotoxic drugs); 6. Past occupational lead exposure history; 7. Drug allergy to calcium disodium edetate; 8. Unable to complete follow-up or provide informed consent.","ALL","18 Years",{"count":38,"type":39},42,"ESTIMATED","INTERVENTIONAL",[42],"NA","Based on previous basic experiments revealing that patients with type 2 diabetic nephropathy exhibit higher blood lead levels than the general population, this study aims to systematically evaluate the impacts of short-term and long-term blood lead exposure on renal function progression in such patients, so as to provide novel epidemiological evidence for clinical intervention.",[45],"Lead-Burdened Type 2 Diabetic Nephropathy","NOT_YET_RECRUITING","2026-07-12",{"date":49,"type":50},"2026-07-16","ACTUAL",{"date":52,"type":39},"2026-08-01",{"date":54,"type":39},"2029-01-01",{"name":5,"class":6}]